We undertook a two-stage genome-wide association study (GWAS) of Alzheimer's disease (AD)
involving over 16,000 individuals, the most powerful AD GWAS to date. In stage 1 (3,941 …

Parkinson's disease is a complex neurodegenerative disorder for which both rare and
common genetic variants contribute to disease risk, onset, and progression. Mutations in more …

Parkinson's disease (PD; OMIM #168600) is the second most common neurodegenerative
disorder in the Western world and presents as a progressive movement disorder. The …

We sought to identify new susceptibility loci for Alzheimer's disease through a staged
association study (GERAD+) and by testing suggestive loci reported by the Alzheimer's Disease …

We performed a genome-wide association study (GWAS) in 1,713 individuals of European
ancestry with Parkinson's disease (PD) and 3,978 controls. After replication in 3,361 cases …

Schizophrenia is a devastating neurodevelopmental disorder whose genetic influences remain
elusive. We hypothesize that individually rare structural variants contribute to the illness. …

We conducted a meta-analysis of Parkinson's disease genome-wide association studies
using a common set of 7,893,274 variants across 13,708 cases and 95,282 controls. Twenty-six …

Identifying the downstream effects of disease-associated SNPs is challenging. To help
overcome this problem, we performed expression quantitative trait locus (eQTL) meta-analysis in …

Background Genome-wide association studies (GWAS) in Parkinson's disease have increased
the scope of biological knowledge about the disease over the past decade. We aimed to …

Common variant genome-wide association studies (GWASs) have, to date, identified >24
risk loci for Parkinson's disease (PD). To discover additional loci, we carried out a GWAS …